Raymond J. Deshaies | |
|---|---|
| Born | September 25, 1961 |
| Nationality | American |
| Alma mater | University of California, Berkeley (PhD) Cornell University (BS) |
| Known for | Discoveries of cullin–RING ubiquitin ligases and elucidation of their mechanism of action and regulation, the JAMM family of ubiquitin isopeptidases, PROTACs (heterobifunctional small molecules that promote target degradation) the Sec61 translocon, and nucleolar sequestration as a regulatory mechanism. Founder of Proteolix, which developed carfilzomib/Kyprolis® |
| Scientific career | |
| Fields | Biochemistry, Cell Biology |
| Institutions | Amgen California Institute of Technology |
| Doctoral advisor | Randy Schekman |
Raymond Joseph Deshaies (born September 25, 1961) is an American biochemist and cell biologist. He is senior vice president of global research at Amgen and a visiting associate at the California Institute of Technology (Caltech). Prior to that, he was a professor of biology at Caltech and an investigator of the Howard Hughes Medical Institute. He is also the co-founder of the biotechnology companies Proteolix and Cleave Biosciences. His research focuses on mechanisms and regulation of protein homeostasis in eukaryotic cells, with a particular focus on how proteins are conjugated with ubiquitin and degraded by the proteasome.